Key result
High-dose levosimendan reduced TNF-α, IL-1β, IL-6, and MCP-1 levels by 10 hours in a rat model of LPS-induced sepsis.
Why the study?
Levosimendan has been proposed to exert anti-inflammatory effects, but data regarding its immunomodulatory effects in early sepsis remain scarce.
Does levosimendan reduce inflammatory cytokines in a rat model of LPS-induced sepsis?
RCT (n=32)
randomly assigned
Does levosimendan reduce inflammatory cytokines in a rat model of LPS-induced sepsis?
High-dose levosimendan demonstrates time- and dose-dependent anti-inflammatory effects in a rat model of LPS-induced sepsis, suggesting potential immunomodulatory benefits.
Answers are grounded in this paper and cite their sources.
Animal data on levosimendan in sepsis should not guide therapy; leaves open dose- and time-dependent cytokine effects for clinical investigation.
Sepsis is a life-threatening condition driven by a dysregulated host immune response to infection, with cytokine overproduction contributing to organ dysfunction and high mortality. Levosimendan, a calcium sensitizer used in acute heart failure, has been proposed to exert anti-inflammatory effects, but information on its immunomodulatory effects in early sepsis remains scarce. This study aimed to investigate the dose- and time-dependent effects of levosimendan on cytokine profiles in a rat model of lipopolysaccharide (LPS)-induced sepsis. Thirty-two male Wistar albino rats were randomly assigned to four groups: sham, sepsis control, low-dose levosimendan (1 mg/kg), and high-dose levosimendan (2 mg/kg). Cytokine levels (TNF-α, IL-1β, IL-6, IL-8, IL-17, MCP-1) were measured at 5 and 10 h post-LPS administration. High-dose levosimendan significantly reduced TNF-α, IL-1β, IL-6, and MCP-1 levels by the 10th hour, accompanied by improved Murine Sepsis Scores. IL-17 and IL-6 showed biphasic responses, increasing initially and decreasing significantly later, particularly with high-dose treatment. IL-8 reduction was observed only in the high-dose group. These findings support levosimendan's dose and time-dependent anti-inflammatory effects and suggest it may modulate both early and late-phase cytokines in sepsis. Further studies are warranted to clarify its potential role in clinical sepsis management.
No takes yet. Share an insight, caveat, or question.
Ertanıdır et al. (2025) conducted an RCT in lipopolysaccharide (LPS)-induced sepsis (n=32). Levosimendan vs. Sham and sepsis control was evaluated on Cytokine levels (TNF-α, IL-1β, IL-6, IL-8, IL-17, MCP-1) at 5 and 10 h post-LPS administration. High-dose levosimendan reduced TNF-α, IL-1β, IL-6, and MCP-1 levels by 10 hours in a rat model of LPS-induced sepsis.
Synapse has enriched 10 related papers. Consider them for comparative context: